An Extension Study of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATLD)

NCT05146882 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Update to Program Design - No Participants Enrolled

Conditions

Alpha 1-Antitrypsin Deficiency

Interventions

DRUG: Belcesiran

Sponsor

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company